• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: S&P 500 survives test of 50-day -2-

    UPDATE: S&P 500 survives test of 50-day -2-

  2. UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

    UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

  3. Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report 2017: High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics - Research and Markets

    Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report 2017: High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics - Research and Markets

  4. UPDATE: Charting the U.S. stock markets' bearish near-term technical tilt

    UPDATE: Charting the U.S. stock markets' bearish near-term technical tilt

  5. UPDATE: Charting the U.S. stock markets' -2-

    UPDATE: Charting the U.S. stock markets' -2-

  6. UPDATE: Charting the March cross currents, S&P 500 presses support ahead of the Fed

    UPDATE: Charting the March cross currents, S&P 500 presses support ahead of the Fed

  7. UPDATE: Charting the March cross currents, S&P -2-

    UPDATE: Charting the March cross currents, S&P -2-

  8. Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

    Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

  9. Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

    Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

  10. Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

    Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

1234

©2017 Morningstar Advisor. All right reserved.